Research
Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg) and dual GIP/GLP-1 agonists (tirzepatide) reduce major adverse cardiovascular events (MACE) in obese patients without diabetes, independent of weight loss alone.
If you are obese and have existing heart disease, ask your doctor about GLP-1 agonists like semaglutide. They significantly lower your risk of heart attack and stroke, offering protection beyond just weight loss.
StrongSupportsVERY_HIGH confidence
The SELECT trial... produced a 20% reduction in MACE, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke... These findings are consistent with current evidence in obese individuals without diabetes.
Why this rating
Based on large-scale randomized controlled trials (SELECT, n=17,604) with statistically significant results (P < 0.001).
Source
Pharmacological therapy in the obese patient: is it only a matter of fat loss?
Claudio Borghi et al. · European Heart Journal Supplements · 2026
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →